Immunome, Inc. (IMNM) SEC Filings & Earnings Calls

Dilution from equity issuance; cash burn of $20M.

“Paid $20M cash and issued 4.43M shares; no milestone/royalty obligations remain.”

Clinical trial failure risk

“The Company has incurred significant operating losses since inception and expects to continue to incur losses from operations for the foreseeable future as it pursues development and seeks regulatory approval of its therapeutic candidates and other programs.” · word for word

Regulatory approval risk

“We submitted a new drug application, or NDA, for varegacestat in April 2026, which has been accepted by the U.S. Food and Drug Administration, or FDA, and assigned a Prescription Drug User Fee Act, or PDUFA, target action date of April 28, 2027.” · word for word

Cash burn risk

“Net cash used in operating activities (120,330) for the six months ended June 30, 2026”

Dependence on varegacestat approval and commercial success; regulatory and clinical risks.

“Varegacestat PDUFA target action date set for April 28, 2027; no guarantee of approval.” · word for word

Significant net loss and high R&D spending; no revenue from product sales.

“Net loss of $73.1 million; R&D expenses $59.9 million.”

Pre-revenue biotech with significant R&D spend; regulatory and clinical risks.

“Net loss $53.8M; no revenue; reliance on pipeline success.”

No product revenue; reliance on equity financing

“We have not generated any product revenue to date and do not expect to generate product revenue until it successfully completes development and obtains regulatory approval for at least one of its product candidates.”

Increasing cash burn

“Net cash used in operating activities for the three months ended March 31, 2026 was $58.6 million.” · word for word

Dependence on varegacestat approval

“We submitted a new drug application, or NDA, for varegacestat in April 2026.” · word for word

Clinical trial failure risk

“No forward-looking statement can be guaranteed and actual results may differ materially from those stated or implied by forward-looking statements.” · word for word

Regulatory approval risk

“Forward-looking statements should be evaluated together with the many risks and uncertainties that affect our business, particularly those mentioned under the 'Risk Factors' heading of our Annual Report on Form 10-K for the year ended December 31, 2025.” · word for word

Clinical trial failure risk

“We are a biopharmaceutical company with a history of losses. We expect to continue to incur significant losses for the foreseeable future and may never achieve or maintain profitability.” · word for word

Regulatory approval risk

“We have not yet submitted a New Drug Application, or NDA, or Biologics License Application, or BLA, obtained FDA approval for marketing, or successfully commercialized a product, and we may be unable to do so.” · word for word

Competition risk

“We face substantial competition, which may result in others discovering, developing or commercializing products more quickly or marketing them more successfully than us.” · word for word

Financing risk

“We expect to continue to incur significant losses for the foreseeable future and may never achieve or maintain profitability.” · word for word

Dilution from equity offering.

“Underwriting agreement for equity offering.”

Regulatory and commercial risks for varegacestat if approved

“NDA submission may be delayed; labeling and market acceptance risks”

Pre-revenue clinical-stage company with no product revenue

“The Company has not generated any product revenue to date and does not expect to generate product revenue until it successfully completes development and obtains regulatory approval for at least one of its product candidates.” · word for word

Dependence on equity financing for operations

“Through September 30, 2025, the Company has funded its operations primarily through sales of equity securities.” · word for word

Clinical trial and regulatory risk for pipeline assets

“The Company is subject to risks and uncertainties common to companies in the biotechnology industry at Immunome's stage including, but not limited to, risks associated with research, development, and manufacturing activities, uncertain results of preclinical and clinical testing.” · word for word

Collaboration revenue ended with AbbVie termination

“The Collaboration Agreement terminated pursuant to its terms in July 2025.” · word for word

Clinical trial risk for varegacestat and IM-1021

“topline data for the Phase 3 RINGSIDE Part B study before the end of 2025; objective responses observed but early stage” · word for word

Dependence on pipeline success

“No approved products; all programs are clinical or preclinical”